| 01/26 | Eisai : Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer.. | AQ |
| 01/26 | European Medicines Agency accepts Marketing Authorization Application for lecanemab as .. | AQ |
| 01/17 | Eisai : Aims to advance gastrointestinal cancer treatment with research across multiple tu.. | PU |
| 01/15 | Eisai, Biogen apply for Alzheimer's drug approval in Japan | AQ |
| 01/12 | Eisai : Launches renewed sustainability page | PU |
| 01/10 | BioArctic's partner Eisai submits marketing authorization application for lecanemab as .. | AQ |
| 01/09 | Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approva.. | AQ |
| 01/09 | FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Tr.. | AQ |
| 01/07 | Explainer : New drug slows Alzheimer's but comes with caveats | AQ |
| 01/06 | Eisai : Submits Supplemental Biologics License Application to FDA for Traditional Approval.. | PU |
| 01/06 | BioArctic's partner Eisai submits supplemental Biologics License Application to FDA for.. | AQ |
| 01/06 | U.S. regulators OK Alzheimer's drug developed by Japan's Eisai | AQ |
| 01/06 | US approves Alzheimer's drug that modestly slows disease | AQ |
| 01/06 | Alzheimer's drug that modestly slows disease OK'd by FDA | AQ |
| 01/06 | Eisai : FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathwa.. | PU |
| 2022 | BioArctic's partner Eisai publishes statement relating to article on lecanemab in Scien.. | AQ |
| 2022 | BioArctic's partner Eisai initiates BLA submission of data for lecanemab in China | AQ |
| 2022 | Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United Stat.. | AQ |
| 2022 | Eisai : TO DIVEST RIGHTS FOR ANTI-EPILEPTIC DRUG FYCOMPA® (perampanel) CIII IN UNITED STAT.. | PU |
| 2022 | Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensiv.. | AQ |
| 2022 | Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio .. | AQ |
| 2022 | Eisai - eleven experts from leading medical institutions and eight experts from eisai p.. | AQ |
| 2022 | Eisai presents full results of lecanemab phase 3 confirmatory clarity ad study for earl.. | AQ |
| 2022 | Landmark Alzheimer's drug slows down disease in early stages | AQ |
| 2022 | Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish F.. | AQ |
| 2022 | Drug slows Alzheimer's but can it make a real difference? | AQ |
| 2022 | BioArctic's partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD.. | AQ |
| 2022 | Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's d.. | AQ |
| 2022 | Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Ar.. | AQ |
| 2022 | Eisai to present latest data on fycompa ciii at the 76th american epilepsy society annu.. | AQ |
| 2022 | Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) .. | AQ |
| 2022 | To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadz.. | AQ |
| 2022 | Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clar.. | AQ |
| 2022 | Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid.. | AQ |
| 2022 | Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance.. | AQ |
| 2022 | Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Tre.. | AQ |
| 2022 | Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon | AQ |
| 2022 | Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and .. | AQ |
| 2022 | Altoida Celebrates Historic Day for Patients with Alzheimer's Disease | AQ |
| 2022 | Alzinova AB interim report January - September 2022 | AQ |
| 2022 | Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA Monotherap.. | AQ |
| 2022 | Interim Report for the period July - September 2022 | AQ |
| 2022 | Eisai Completes Construction of Its New Injection/Research Building at Kawashima Indust.. | AQ |
| 2022 | Addf statement on topline results of phase 3 trial of amyloid-clearing drug lecanemab | AQ |
| 2022 | Alzheimer's drug shows promise in early results of study | AQ |
| 2022 | Eisai - lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing h.. | AQ |
| 2022 | Update1 : Alzheimer's drug proves effective in slowing symptoms, says Eisai | AQ |
| 2022 | Alzheimer's drug proves effective in slowing symptoms, says Eisai | AQ |
| 2022 | Eisai's Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint | AQ |
| 2022 | Eisai : Lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing high.. | PU |
| 2022 | Lecanemab phase 3 Clarity AD study in early Alzheimer's disease meets primary and all k.. | AQ |
| 2022 | Eisai : Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheum.. | AQ |
| 2022 | Merck and eisai present results from phase 3 leap-002 trial evaluating keytruda plus le.. | AQ |
| 2022 | Eisai presents results of post-hoc analysis of eribulin mesylate at the european societ.. | AQ |
| 2022 | Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENV.. | AQ |
| 2022 | Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the Europ.. | AQ |
| 2022 | Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022 | AQ |
| 2022 | Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and P.. | AQ |
| 2022 | C2n and eisai collaborate to build awareness and real-world evidence for blood-based as.. | AQ |
| 2022 | Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-b.. | AQ |
| 2022 | Eisai - baseball legend bernie williams teams up with eisai and advocacy partners to la.. | AQ |
| 2022 | Eisai : CONSOLIDATED FINANCIAL REPORT for the Three-Month Period Ended June 30,2022 | PU |
| 2022 | Eisai : FY 2022 (Ending March 31, 2023) First Quarter Financial Results Reference Data | PU |
| 2022 | Merck and eisai provide update on phase 3 leap-002 trial evaluating keytruda (pembroliz.. | AQ |
| 2022 | Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and.. | AQ |
| 2022 | Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial | AQ |
| 2022 | Eisai : and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Ev.. | PU |
| 2022 | Latest data on lecanemab to be presented at Alzheimer's Association International Confe.. | AQ |
| 2022 | Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series | AQ |
| 2022 | Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022 | AQ |
| 2022 | Eisai : To present the latest lecanemab data, including aria-e and subcutaneous formulatio.. | PU |
| 2022 | Interim Report for the period April - June 2022 | AQ |
| 2022 | Eisai Co., Ltd. - THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS.. | AQ |
| 2022 | U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application o.. | AQ |
| 2022 | The FDA accepts BLA and grants priority review for lecanemab for treatment of early Alz.. | AQ |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
